Joincare Pharmaceutical Group Industry Co., Ltd. (600380.SH) Latest Company News

Oct 26, 2026, 09:28 UTC
Healthgen reported revenue of 9.671 billion yuan, down 15.74% year over year, and net profit attributable to shareholders of 887 million yuan, down 18.76%, for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 26, 2026, 09:28 UTC
Healthgen reported third-quarter 2026 revenue of 3.088 billion yuan, down 13.73% year over year, and net profit attributable to shareholders of 239 million yuan, down 22.01%.
Source:
- finance.sina.cn
Sep 29, 2026, 09:27 UTC
Shanghai Livzon, a subsidiary of Livzon Pharmaceutical Group, received approval from China's National Medical Products Administration to launch a 11.25mg (3-month) formulation of leuprorelin acetate microspheres for injection.
Source:
- finance.sina.cn
- aastocks.com
Sep 12, 2026, 08:15 UTC
Zhu Baoguo resigned as chairman, director and legal representative of Joincare Pharmaceutical Group for retirement reasons, effective upon delivery of his resignation, and Lin Nanqi was elected chairman of the ninth board.
Source:
- finance.sina.cn
Jul 27, 2026, 09:21 UTC
Health Yuan announced it will provide an additional 40 million yuan entrusted loan to its controlled subsidiary Jiaozuo Jianfeng, with a five-year term and interest rate based on the one-year LPR, while also adjusting the interest rate on existing entrusted loans to the one-year LPR.
Source:
- finance.sina.cn
Jul 27, 2026, 07:56 UTC
Joincare Pharmaceutical Group announced that its product Marpasivir Capsules (brand name: Yilikang) has been officially launched for sale, with market promotion and channel deployment ongoing.
Source:
- wap.eastmoney.com

600380.SH

Healthgen reported revenue of 9.671 billion yuan, down 15.74% year over year, and net profit attributable to shareholders of 887 million yuan, down 18.76%, for the first three quarters of 2026.

Healthgen reported third-quarter 2026 revenue of 3.088 billion yuan, down 13.73% year over year, and net profit attributable to shareholders of 239 million yuan, down 22.01%.

Shanghai Livzon, a subsidiary of Livzon Pharmaceutical Group, received approval from China's National Medical Products Administration to launch a 11.25mg (3-month) formulation of leuprorelin acetate microspheres for injection.

Zhu Baoguo resigned as chairman, director and legal representative of Joincare Pharmaceutical Group for retirement reasons, effective upon delivery of his resignation, and Lin Nanqi was elected chairman of the ninth board.

Health Yuan announced it will provide an additional 40 million yuan entrusted loan to its controlled subsidiary Jiaozuo Jianfeng, with a five-year term and interest rate based on the one-year LPR, while also adjusting the interest rate on existing entrusted loans to the one-year LPR.

Joincare Pharmaceutical Group announced that its product Marpasivir Capsules (brand name: Yilikang) has been officially launched for sale, with market promotion and channel deployment ongoing.